Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.64 |
| ▸ | MAOB | P27338 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | AGXT | P21549 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949595 | 0.86 | MRGPRX4 (0.57) | MRGPRX4CYP2C19 | |
| SCHEMBL15701557 | 0.85 | MRGPRX4 (0.67) | MRGPRX4MAOBKDM4EFFAR4HTR6 | |
| SCHEMBL12524900 | 0.84 | MRGPRX4 (0.62) | MRGPRX4MAOBKDM4EFFAR4HTR6 | |
| SCHEMBL12295554 | 0.83 | MRGPRX4 (0.68) | MRGPRX4KDM4EFFAR4MAPTL3MBTL1 | |
| SCHEMBL15701549 | 0.83 | EGFR (0.47) | MRGPRX4MAOBSLC6A4IDO1AGXT | |
| SCHEMBL2558750 | 0.82 | MRGPRX4 (0.64) | MRGPRX4KDM4EFFAR4 | |
| SCHEMBL1406384 | 0.81 | MAOB (0.61) | MRGPRX4MAOBHTR6IDO1AGXT | |
| SCHEMBL12261786 | 0.81 | MAOB (0.65) | MAOB | |
| SCHEMBL9946102 | 0.81 | MRGPRX4 (0.62) | MRGPRX4KDM4EFFAR4 | |
| SCHEMBL12301124 | 0.80 | MRGPRX4 (0.58) | MRGPRX4MAOBKDM4EHTR6IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524956-B2 | Alkyne substituted quinazoline compound and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210047303-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | KANION USA INC. | 2021-02-18 | — | — | US | disclosed |
| US-20180093975-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. | 2018-04-05 | — | — | US | disclosed |
| US-20180093975-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. | 2018-04-05 | — | — | US | disclosed |
| US-20160031860-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS INC (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031860-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS INC (US) | 2016-02-04 | — | — | US | disclosed |
| US-9187459-B2 | Quinazoline-7-ether compounds and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9090588-B2 | Alkyne substituted quinazoline compound and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090588-B2 | Alkyne substituted quinazoline compound and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140221406-A1 | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140128417-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128417-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2014-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128417-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | ERBB2, ERBB4, ERBB3 | MRGPRX4 2689/4885MAOB 2081/4885KDM4E 1564/4885 |
| US-20160031860-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | ERBB2, ERBB4, ERBB3 | MRGPRX4 2689/4885MAOB 2081/4885KDM4E 1564/4885 |
| US-20140221406-A1 | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | ABL1, ERBB4, ERBB2 | MRGPRX4 1325/4885MAOB 3202/4885KDM4E 691/4885 |
| US-11524956-B2 | Alkyne substituted quinazoline compound and methods of use | ERBB2, ERBB4, ERBB3 | MRGPRX4 2689/4885MAOB 2081/4885KDM4E 1564/4885 |
| US-20180093975-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | ERBB2, ERBB4, ERBB3 | MRGPRX4 2689/4885MAOB 2081/4885KDM4E 1564/4885 |
| US-20210047303-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | ERBB2, ERBB4, ERBB3 | MRGPRX4 2689/4885MAOB 2081/4885KDM4E 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.